Christoph Roellig, MD

Articles by Christoph Roellig, MD

Dr. Roellig on FLT3 ITD/NPM1 Mutation Status for Patients With AML

September 22nd 2015

Christoph Roellig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with AML who are in first remission.

Latest Updated Articles

Dr. Roellig on FLT3 ITD/NPM1 Mutation Status for Patients With AML
Published: September 22nd 2015 | Updated:

Christoph Roellig, MD

Articles by Christoph Roellig, MD

Dr. Roellig on FLT3 ITD/NPM1 Mutation Status for Patients With AML

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma